Create
Log in
Sign up
Golden has been acquired by ComplyAdvantage.
Read about it here ⟶
US Patent 11851442 Tricyclic fused thiophene derivatives as JAK inhibitors
Overview
Structured Data
Issues
Contributors
Activity
Access by API
Access by API
Is a
Patent
0
Date Filed
August 12, 2021
0
Date of Patent
December 26, 2023
0
Patent Application Number
17400861
0
Patent Citations
US Patent 8415362 Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
0
US Patent 9498467 Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
0
US Patent 9777017 Tricyclic fused thiophene derivatives as JAK inhibitors
0
US Patent 9802957 Processes of preparing a JAK1 inhibitor and new forms thereto
0
US Patent 9908895 Tricyclic fused thiophene derivatives as JAK inhibitors
0
US Patent 10053465 Pyrrolopyrimidine derivatives as TAM inhibitors
0
US Patent 10064866 Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors
0
US Patent 10077277 Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
0
US Patent 10370387 Tricyclic fused thiophene derivatives as JAK inhibitors
0
US Patent 10450325 Processes of preparing a JAK1 inhibitor and new forms thereto
0
•••
Patent Inventor Names
Wenyu Zhu
0
Song Mei
0
Joseph Glenn
0
Yun-Long Li
0
Patent Jurisdiction
United States Patent and Trademark Office
0
Patent Number
11851442
0
Patent Primary Examiner
Daniel R Carcanague
0
CPC Code
A61K 31/437
0
C07D 495/12
0
C07D 495/14
0
Find more entities like US Patent 11851442 Tricyclic fused thiophene derivatives as JAK inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Company
Home
Press & Media
Blog
Careers
WE'RE HIRING
Products
Knowledge Graph
Query Tool
Data Requests
Knowledge Storage
API
Pricing
Enterprise
ChatGPT Plugin
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
By using this site, you agree to our
Terms of Service
.
SUBSCRIBE